Business Context and Reporting Period
Company: Achieve Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 7, 2019
Reporting Period: Event date of June 7, 2019
The Company entered into a material definitive agreement to establish an "At The Market" (ATM) equity offering program.
Key Financial Metrics
This filing does not contain periodic financial statements (e.g., revenue, profit, cash flow, or margins). The only financial metric disclosed relates to the new financing facility:
- Maximum Offering Size: Up to $6.0 million in aggregate gross proceeds.
- Commission Rate: 3.0% of aggregate gross proceeds payable to the agent.
- Security Type: Common Stock, par value $0.001 per share.
Material Changes
The primary material change is the execution of an At The Market Offering Agreement with H.C. Wainwright & Co., LLC. This agreement allows the Company to sell shares from time to time based on market conditions. The filing does not provide comparative financial data against prior periods.
Outlook, Risks, and Management Commentary
- Offering Mechanism: Sales will be made via ordinary brokers' transactions on The Nasdaq Capital Market at prevailing market prices.
- Termination: The agreement terminates upon the earliest of: (a) sale of all shares, (b) termination by either party, or (c) June 7, 2022.
- Discretion: The Company is not obligated to sell any shares under the agreement.
- Costs: The Company will pay a 3.0% commission and reimburse certain specified expenses to H.C. Wainwright.
Investor Verification Checklist
- Verify the current share price and trading volume on The Nasdaq Capital Market to assess potential dilution impact.
- Review the shelf registration statement (File No. 333-229019) and the prospectus supplement dated June 7, 2019, for full terms.
- Monitor future 8-K filings or quarterly reports to track the actual volume of shares sold under this ATM program.
- Confirm the Company's current cash position and liquidity needs to understand the urgency of utilizing this facility.